Stock Research Monitor: BEAT, CGIX, and CHEK
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on BRKR sign up now at www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), Cancer Genetics Inc. (NASDAQ: CGIX), and Check-Cap Ltd (NASDAQ: CHEK). Companies in the Medical Laboratories and Research category is very small from a dividend perspective. These firms, as a whole, tend to offer higher dividend yields than the wider healthcare sector. All you have to do is sign up today for this free limited time offer by clicking the link below.
Shares in Malvern, Pennsylvania headquartered BioTelemetry Inc. rose 1.68%, ending Thursday's trading session at $42.45. The stock recorded a trading volume of 239,908 shares. The Company's shares have surged 25.78% in the last month, 22.33% over the last three months, and 51.88% over the past year. The stock is trading 18.63% and 29.31% above its 50-day and 200-day moving averages, respectively. Moreover, shares of BioTelemetry, which provides cardiac and mobile blood glucose monitoring, centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries, have a Relative Strength Index (RSI) of 73.21.
On April 26th, 2018, research firm The Benchmark Company reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $44 a share to $46 a share. Get the full research report on BEAT for free by clicking below at:
Billerica, Massachusetts headquartered Bruker Corp.'s stock declined slightly by 0.90%, closing the day at $30.74. A total volume of 725,877 shares was traded, which was above their three months average volume of 595,220 shares. The Company's shares have advanced 2.88% in the past month and 14.06% over the past year. The stock is trading 2.13% above its 50-day moving average. Additionally, shares of Bruker, which manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the US, Europe, Asia/Pacific, and internationally, have an RSI of 54.61.
On May 14th, 2018, Bruker announced that its Board of Directors has approved payment of a quarterly cash dividend, in the amount of $0.04 per share, on the Company's common stock. The dividend will be paid on June 22nd, 2018, to stockholders of record as of June 04th, 2018. Access the free research report on BRKR now by signing up at:
On Thursday, shares in Rutherford, New Jersey-based Cancer Genetics Inc. recorded a trading volume of 166,207 shares. The stock ended the day 6.26% lower at $0.98. The Company's shares have advanced 4.25% in the past month. The stock is trading below its 50-day moving average by 19.10%. Furthermore, shares of Cancer Genetics, which develops, commercializes, and provides molecular and biomarker-based tests and services in the US, India, and China, have an RSI of 44.51.
On May 15th, 2018, Cancer Genetics announced its results for the first quarter ended March 31st, 2018. Total revenue was $7.7 million for Q1 2018, gross profit margin was 33.7%, total operating expenses were approximately $7.5 million, and net loss was $(4.5) million. As of March 31st, 2018, cash and cash equivalents, excluding restricted cash of $0.4 million totaled $4.0 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on CGIX at:
Isfiya, Israel-based Check-Cap Ltd's stock dropped 1.59%, finishing yesterday's session at $4.34 with a total trading volume of 610,225 shares. The stock is trading below their 50-day moving average by 29.93%. Shares of the Company, which engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel, have an RSI of 43.10.
On May 22nd, 2018, Check-Cap announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy, which was submitted for capsule CE Mark, received in January 2018, has been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology. Aspiring Member, please take a moment to register below for your free research report on CHEK at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities